Filipe Pinto1,2, Nathalia C Campanella3, Lucas F Abrahão-Machado4, Cristovam Scapulatempo-Neto3,4, Antonio T de Oliveira3,5, Maria J Brito6, Raquel P Andrade7, Denise P Guimarães3,8, Rui M Reis9,10,11. 1. Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal. 2. ICVS/3B's-PT Government Associate Laboratory, Braga, Guimarães, Portugal. 3. Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, Barretos, CEP 14784 400, Sao Paulo, Brazil. 4. Department of Pathology, Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil. 5. Upper Digestive Surgery Department, Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil. 6. Department of Pathology, Hospital Garcia de Orta, Almada, Portugal. 7. Regenerative Medicine Program, Department of Medicine and Biomedical Sciences, University of Algarve, Faro, Portugal. 8. Department of Endoscopy, Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil. 9. Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal. ruireis.hcb@gmail.com. 10. ICVS/3B's-PT Government Associate Laboratory, Braga, Guimarães, Portugal. ruireis.hcb@gmail.com. 11. Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, Barretos, CEP 14784 400, Sao Paulo, Brazil. ruireis.hcb@gmail.com.
Abstract
BACKGROUND: The T-box transcription factor Brachyury was recently reported to be upregulated and associated with prognosis in solid tumors. Here, we proposed to evaluate the potential use of Brachyury protein expression as a new prognostic biomarker in gastrointestinal stromal tumors (GIST). METHODS: Brachyury protein expression was analyzed by immunohistochemistry in a cohort of 63 bona fide GIST patients. Brachyury expression profiles were correlated with patients' clinicopathological features and prognostic impact. Additionally, an in silico analysis was performed using the Oncomine database to assess Brachyury alterations at DNA and mRNA levels in GISTs. RESULTS: We found that Brachyury was overexpressed in the majority (81.0 %) of primary GISTs. We observed Brachyury staining in the nucleus alone in 4.8 % of cases, 23.8 % depicted only cytoplasm staining, and 52.4 % of cases exhibited both nucleus and cytoplasm immunostaining. The presence of Brachyury was associated with aggressive GIST clinicopathological features. Particularly, Brachyury nuclear (with or without cytoplasm) staining was associated with the presence of metastasis, while cytoplasm sublocalization alone was correlated with poor patient survival. CONCLUSIONS: Herein, we demonstrate that Brachyury is overexpressed in GISTs and is associated with worse outcome, constituting a novel prognostic biomarker and a putative target for GIST treatment.
BACKGROUND: The T-box transcription factor Brachyury was recently reported to be upregulated and associated with prognosis in solid tumors. Here, we proposed to evaluate the potential use of Brachyury protein expression as a new prognostic biomarker in gastrointestinal stromal tumors (GIST). METHODS:Brachyury protein expression was analyzed by immunohistochemistry in a cohort of 63 bona fide GIST patients. Brachyury expression profiles were correlated with patients' clinicopathological features and prognostic impact. Additionally, an in silico analysis was performed using the Oncomine database to assess Brachyury alterations at DNA and mRNA levels in GISTs. RESULTS: We found that Brachyury was overexpressed in the majority (81.0 %) of primary GISTs. We observed Brachyury staining in the nucleus alone in 4.8 % of cases, 23.8 % depicted only cytoplasm staining, and 52.4 % of cases exhibited both nucleus and cytoplasm immunostaining. The presence of Brachyury was associated with aggressive GIST clinicopathological features. Particularly, Brachyury nuclear (with or without cytoplasm) staining was associated with the presence of metastasis, while cytoplasm sublocalization alone was correlated with poor patient survival. CONCLUSIONS: Herein, we demonstrate that Brachyury is overexpressed in GISTs and is associated with worse outcome, constituting a novel prognostic biomarker and a putative target for GIST treatment.
Authors: Romaine I Fernando; Marianne D Castillo; Mary Litzinger; Duane H Hamilton; Claudia Palena Journal: Cancer Res Date: 2011-06-08 Impact factor: 12.701
Authors: Cristina R Antonescu; Peter Besmer; Tianhua Guo; Knarik Arkun; Glory Hom; Beata Koryotowski; Margaret A Leversha; Philip D Jeffrey; Diann Desantis; Samuel Singer; Murray F Brennan; Robert G Maki; Ronald P DeMatteo Journal: Clin Cancer Res Date: 2005-06-01 Impact factor: 12.531
Authors: Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544
Authors: Nathália C Campanella; António T de Oliveira; Cristovam Scapulatempo-Neto; Denise P Guimarães; Rui M Reis Journal: Recent Pat Anticancer Drug Discov Date: 2013-09 Impact factor: 4.169
Authors: Christopher R Heery; Claudia Palena; Sheri McMahon; Renee N Donahue; Lauren M Lepone; Italia Grenga; Ulrike Dirmeier; Lisa Cordes; Jenn Marté; William Dahut; Harpreet Singh; Ravi A Madan; Romaine I Fernando; Duane H Hamilton; Jeffrey Schlom; James L Gulley Journal: Clin Cancer Res Date: 2017-08-30 Impact factor: 12.531
Authors: Sagar R Shah; Justin M David; Nathaniel D Tippens; Ahmed Mohyeldin; Juan C Martinez-Gutierrez; Sara Ganaha; Paula Schiapparelli; Duane H Hamilton; Claudia Palena; Andre Levchenko; Alfredo Quiñones-Hinojosa Journal: Cell Rep Date: 2017-10-10 Impact factor: 9.423